Roundtable II: Cost concerns for rheumatoid arthritis treatment

American Journal of Managed Care

Volumn 5, Issue 14 SUPPL., 1999, Pages

  Kavanaugh, A F ^a   Wolfe, F ^a   Auslander, M ^a   Bresloff, T ^a   Clark, D L ^a   Hillman, D ^a   Lewis, D L ^a   Martinez, L ^a   Milgram, L ^a   Newcomer, D ^a   Nguyen, T ^a   Rae, J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ALGORITHM; CLINICAL PRACTICE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL TOXICITY; HEALTH MAINTENANCE ORGANIZATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; CYTOKINES; DECISION MAKING; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; PATIENT SELECTION; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 0032846169     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)